California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its ...

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

Johns Hopkins University School of Medicine alumnus and former faculty member Hamilton O. Smith, M.D., whose 1978 Nobel Prize-winning discovery of restriction enzymes revolutionized genetic ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...